,18 Nevertheless, osimertinib, which is indicated for treatment of EGFR mutation (EGFRm)-positive NSCLC,17,19 has been associated with increased risk of cardiac-related AEs, notably QTc prolongation and decreased LVEF.6 This evidence concerns the gene EGFR and non-small cell lung carcinoma.